• Yuankai Shi, Xiaohui He, Sheng Yang, Bin Ai, Changgong Zhang, Dingzhi Huang, Mei Dong, Peng Liu, Shengyu Zhou, and Xiaohong Han.
• Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. syk@pubem.cicams.ac.cn
• Chemotherapy. 2007 Jan 1;53(1):44-50.

BackgroundThis study observed and compared the preventive effects of ramosetron and ondansetron on gastrointestinal side effects caused by cisplatin-containing chemotherapy.MethodsFifty patients with malignant tumors undergoing their first chemotherapy were randomly divided into two groups, and each group received 0.3 mg of ramosetron and 16 mg of ondansetron in a prospective crossover comparison study.ResultsData were collected for analysis of the therapeutic effect in 47 cases and for adverse events in 50 cases. Both drugs showed similar results in regard to chemotherapy-induced gastrointestinal side effects, emesis and appetite loss on day 1, but by day 5, ramosetron was significantly better than ondansetron in terms of controlling appetite loss. From days 3-5, ramosetron tended to be more effective than ondansetron in its antiemetic action. The incidence of headache, fatigue and constipation was the same for both drugs.ConclusionsRamosetron is a long-lasting and safe antiemetic agent.Copyright 2007 S. Karger AG, Basel.

28 keywords...

hide…